BACKGROUND: Although outcomes for acute myeloid leukemia (AML) have improved over time, they remain poor overall, and toxicity from both the disease and its treatment can affect quality of life (QOL). One barrier to including QOL endpoints in clinical trials is the lack of a disease-specific QOL instrument that can efficiently capture the major QOL deficits in this population. METHODS: A cross-sectional study was performed to elicit concepts for inclusion in a new AML-specific QOL instrument called the AML-QOL. Eighty-two patients at various stages of disease were interviewed about sources of support (positive concepts) and problems and symptoms (negative concepts) experienced over the past week, and they were asked to grade how much each affected their QOL. In addition, patients were asked to complete 2 validated instruments: the Functional Assessment of Cancer Therapy with the leukemia and transplant modules and the 29-item Patient-Reported Outcomes Measurement Information System questionnaire. RESULTS: With data from the open-ended and questionnaire-based portions of the interview, 7 positive concepts and 64 negative concepts were elicited. From these, 5 positive concepts and 21 negative concepts were selected for inclusion in the preliminary AML-QOL on the basis of concept prevalence and the impact on QOL. CONCLUSIONS: These concepts will form the basis of a new QOL instrument specific to AML.
INTRODUCTION
Despite advances in supportive care, survival with acute myeloid leukemia (AML) and other high-risk myeloid neoplasms is often measured in months rather than years, 1,2 and long-term survival typically requires multi-agent chemotherapy with or without allogeneic hematopoietic cell transplantation (HCT). 3 Because these therapies carry a risk for substantial, potentially life-threatening toxicities and survival for many patients is limited, there is an increasing interest in measuring quality of life (QOL) as well as quantity of life and in incorporating QOL metrics into clinical trials. 4 In the United States, this interest has been encouraged, in part, by the fact that federal regulations support drug approval on the basis of demonstrated clinical benefits, including improvements in QOL. 4, 5 To date, however, relatively few AML studies have incorporated QOL measurements. 6 Several perceived barriers, including a lack of an AML-specific instrument and low survey completion rates in this population, exist, possibly in part because of patient fatigue and questionnaire length. 7 Among the few AML studies to incorporate QOL endpoints, there is heterogeneity in which instrument is used. 6 Some use the European Organization for Research and Treatment of Cancer QLQ-C30 quality-of-life questionnaire, 8 which was developed with lung cancer patients and has not been validated for patients with AML. More recently, studies have incorporated the Functional Assessment of Cancer Therapy (FACT), which can be supplemented with leukemia and transplant modules (Functional Assessment of Cancer Therapy-Leukemia [FACT-LEU] and Functional Assessment of Cancer Therapy-Bone Marrow Transplant [FACT-BMT]). 9 The leukemia module, however, contains some questions more pertinent to chronic leukemias, and the transplant module contains items that would not be relevant in a nontransplant setting. An AML/myelodysplastic syndrome (MDS)-specific symptom checklist, developed by MD Anderson (the MD Anderson Symptom Inventory module for acute myeloid leukemia/ myelodysplastic syndrome), has been published in abstract form, although this measures symptom burden rather than QOL. 10 Non-cancer-specific instruments may also be used; they include the recently developed Patient-Reported
Outcomes Measurement Information System (PROMIS) questionnaires, which include several item banks that can encompass multiple health dimensions. 11 With all of these options, however, there is no consensus on which instrument to use in AML trials. The development of a disease-specific QOL instrument could help to standardize QOL measurement in AML studies, and the resulting instrument may be more responsive and clinically useful than more generic measures. 12 To address these concerns, we conducted a study that elicited concepts for inclusion in a new AML-specific QOL instrument, the AML-QOL, through interviews with patients before, during, and after therapy.
MATERIALS AND METHODS

Patients
English-speaking patients with AML or high-risk MDS undergoing treatment at the University of Washington/ Seattle Cancer Care Alliance were identified through a review of the inpatient census and outpatient clinics. The Fred Hutchinson Cancer Research Center's institutional review board approved the study protocol, and all patients gave written informed consent in accordance with the Declaration of Helsinki.
Data Collection
Sociodemographic information was collected at the baseline. Patients participated in semistructured interviews to elicit symptoms or situations (ie, concepts) that affected their QOL either negatively or positively, with a focus on experiences relevant over the past 7 days: "Tell me about the symptoms that you've experienced over the past week," and "In addition to physical symptoms, people can have emotional symptoms or other sources of stress. Have you had anything like that over the past week?" Interviews were recorded with the participant's permission. For each negative concept, patients were asked to quantify the degree to which each experience affected their QOL on a 3-point scale (little impact, some impact, or high impact). 13 These impact scores were not elicited for positive concepts. Next, patients were asked to report their current Karnofsky performance status.
14 They then completed the English-language Functional Assessment of Cancer Therapy-General (FACT-G) with the FACT-LEU and FACT-BMT subscales (67 total items) as well as the 29-item PROMIS questionnaire. They were asked to "think out loud" and to voice any areas of confusion or perceived ambiguity. Finally, questionnaire responses were reviewed, and responses indicating the presence of any other negative concepts were discussed with patients.
Enrollment continued until no new concepts were elicited (content saturation). To ensure broad applicability of the AML-QOL, efforts were made to enroll patients from the following groups in roughly equal distributions: newly diagnosed patients, initial-chemotherapy patients, relapsed/refractory patients, postchemotherapy patients, patients within 1 year of HCT, and patients more than 1 year after HCT. Furthermore, efforts were made to enroll roughly equal numbers of inpatients and outpatients.
All interviews were conducted by one physician (S.A.B.) and were transcribed verbatim. A codebook was developed on the basis of the initial review of the interviews, and 2 researchers independently coded all interviews (S.A.B. and D.J-S.). Disputed codes were resolved by a third party (S.J.L.). The percentage concordance was determined as the number of agreed-upon codes divided by the number of agreed-upon codes plus the number of codes coded by one researcher but not the other. The concordance in the impact of each concept was calculated similarly among agreed-upon concepts.
Biostatistical Methods
Patient characteristics are reported descriptively. Positive concepts (eg, sources of support) are reported on the basis of prevalence, and their inclusion in the AML-QOL was determined on this basis. Negative concepts (eg, problems and symptoms) were described both by overall prevalence and by the percentage of cases leading to a high impact on QOL. To select concepts for inclusion based on both prevalence and impact, 13 a prevalence-impact score was calculated by multiplication of the prevalence by the impact, and concepts were included in the AML-QOL on the basis of this score with a goal of including approximately 20 to 25 concepts. Logistic regression was used to assess associations between concepts and patient characteristics. Interviews were coded with QDA Miner Lite (Provalis Research, Montreal, Quebec, Canada), and STATA 14 (Stata Corp, College Station, Texas) was used for the analysis.
RESULTS
Patient Characteristics
A total of 100 eligible patients were approached between March and September 2016, and 82 consented to participate. Two patients were eligible but were not approached because their providers felt that they were too ill for an interview. Among the 18 who declined enrollment, 4 reported feeling too ill to participate, whereas 12 declined for other reasons (including not wanting to fill out questionnaires, not having enough time, and not wanting Original Article further interaction with medical staff). Patient demographics are described in Table 1 . Most participants (61%) were inpatient at the time of the interview, and most interviews (78%) were conducted one-on-one without family members present. All interviewees agreed to audio recording. The majority of the patients were married or living with a partner. Approximately half had a college or postgraduate degree. Only 10 (12%) were currently working at least part-time, and they included 7 of the 22 patients (32%) who had completed all planned therapy. All patients had AML except for 4 (5%) with high-risk MDS; these patients were receiving intensive AML-like chemotherapy or were undergoing stem cell transplantation.
Interviews lasted a median of 35.6 minutes (range, 11.3-67.7 minutes). All 82 patients completed the openended portion, whereas 72 completed the FACT instruments, and 68 completed PROMIS.
We coded 7 positive concepts and 64 negative concepts with 75% concordance for concept coding and with 84% concordance for impact coding. Content saturation was achieved after 67 patients, with no new concepts elicited thereafter. The Karnofsky performance status was 80% to 100% for 67% of the patients and 70% or less for 33%.
Positive Concepts
The most commonly described sources of support were family (n 5 70 or 85%), having a positive attitude or hope for the future (n 5 52 or 63%), friends or community (n 5 43 or 52%), trust in the medical team (n 5 43 or 52%), and participation in activities or exercise (n 5 29 or 35%). Less commonly listed were religion or spirituality (n 5 14 or 17%) and being informed about or actively seeking out information on AML (n 5 14 or 17%). We hypothesized that older patients or those with relapsed/refractory disease might rely more heavily on religion or spirituality, that unmarried patients would rely more on friends/community, and that younger patients would rely more on being informed, but we did not find any of these associations: all odds ratios were between 0.95 and 1, and all P values were >.05. Because of the lower prevalence, we did not include concept questions about religion/spirituality or being informed about the disease in the AML-QOL.
Negative Concepts
As shown in Table 2 , the most prevalent symptoms within a week before the interview were also often those deemed most impactful by patients, with several notable exceptions. For example, reduced sexual function and bruising were both reported relatively frequently, but few felt that these seriously affected QOL. Conversely, fevers and taste changes were less often reported but were considered very impactful when they were present. Concepts with a lower prevalence are described in Supporting Table 1 (see online supporting information). Twenty-one negative concepts were selected for inclusion in the AML-QOL on the basis of an apparent cut point on visual inspection (Fig. 1) . Depending on the patient's disease state, different concepts took on greater importance. For example, although fear/anxiety was an important concept in all groups, it was most prevalent/impactful at the initial diagnosis and in patients who had relapsed after HCT. Pain was most important among patients receiving chemotherapy, either for the initial diagnosis or as salvage. Long-term survivors, particularly those having undergone HCT, were particularly concerned about the impact of their disease on their family (Table 3) . Compared with outpatients, inpatients rated many concepts as having a higher prevalence/ impact, particularly concepts dealing with emotion, a loss of control or function, and chemotherapy side effects (Supporting Fig. 1 
[see online supporting information]).
Sources of Ambiguity and Confusion With Validated Instruments
Among the 72 patients who completed at least some of the FACT or PROMIS questionnaires, the most common source of confusion or ambiguity, as expressed by 16 patients, related to decrements in functional status as a result of temporary restrictions (eg, inpatient stays) rather than true functional limitations. This issue arose with both the FACT and PROMIS questionnaires, although they were more common in the latter, where patients were asked about their ability to perform chores ("I'm not able to . . . because I can't get out of the hospital"), housework ("There's nothing to do here"), yard work ("I can't do anything with dirt"), and leisure/social activities ("They won't let me through those [hospital] doors"). Indeed, among patients who reported a Karnofsky performance status of 80% or higher, which indicated an ability to carry on normal activity, 27% reported "much difficulty" or "inability" to do chores. Similarly, this level of difficulty was reported by 29% with leisure activity, by 37% with work, and by 43% with social activity with friends. In contrast, all reported that they could go for a walk of at least 15 minutes without significant difficulty. We hypothesized that circumstantial restrictions would have less impact on QOL than true functional limitations, and when it was possible during interview coding, we indicated whether functional limitations were due to physical inability (eg, they were related to weakness, fatigue, or pain) or temporary restrictions (eg, they were staying in the hospital or clinic housing or had environmental or social restrictions because of a weakened immune system). Indeed, patients were more likely to report a significant QOL impact due to an inability to participate in day-today activities when the limitation was due to physical inability (10 of 15) versus temporary restrictions (1 of 8).
Another source of potential errors, which was described by 14 patients (19%), was directional changes in the Likert scale (eg, from high numbers being "good" to high numbers being "bad".) Most patients caught their own errors related to these changes, although in 4 cases errors were noted only after the survey was completed when patients were asked why they had scored a particular concept as problematic, and it turned out that they had not intended to do so.
Several patients expressed confusion about how to answer questions related to sexual function and satisfaction. Although low libido was discussed in 30 interviews, only 5 patients brought this up unprompted during the initial open-ended concept-elicitation portion of the interview. The majority of the patients reported not being bothered at all by this change, and those who were bothered generally reported that their biggest concern was the effect of this change on their partners rather than themselves (and they scored the impact of their disease on their family as being very impactful accordingly). Along the same lines, some patients reported ambiguity concerning questions about concepts that predated and were unaffected by the leukemia diagnosis, including low libido, blurry vision, and satisfaction with physical appearance. For example, 7 patients reported unchanged blurry vision due to longstanding issues, often corrected with glasses, and they wondered how they should score a question on this concept. Three scored this low (0 or 1), 1 scored it as intermediate (2) and 3 scored it as high (3 or 4).
Finally, several words in the surveys were unclear to patients. Seven patients reported uncertainty about the concept of acceptance and indicated that neither they nor their families had accepted their illness because this would indicate acquiescence, a loss of hope, or stopping treatment: "To me, that almost means . . . just going along with it. It's a negative connotation." No patient reported confusion over the question about lymphadenopathy, which was phrased as "lumps or swelling," although among the 11 who responded at least "somewhat" to this question, only 2 were referring to lymphadenopathy; the others referred to soft-tissue infections, edema, or bruises. Five patients reported that they were unsure what "tremors" were; when prompted, 2 guessed correctly.
Qualitative Results Versus Quantitative Results
For some concepts, quantitative results from FACT and PROMIS seemed to underestimate the burden in comparison with the qualitative open-ended interview. For example, in the semistructured interviews, 80% of the patients expressed fear/anxiety, with 42% and 66% of those noting a high impact or some/high impact, respectively. In contrast, among the participants responding to the 4 anxiety-related items on the 29-item PROMIS questionnaire, only 15% to 40% responded positively (score 3 on a 1-5 scale), and 4% to 12% responded strongly (score 4). Similarly, among those responding to the 3 related items on FACT-G, only 25% to 42% responded positively (score 2 on a 0-4 scale), and 15% to 24% responded strongly (score 3). Likewise, for pain, the 29-item PROMIS questionnaire has 4 questions on the impact that pain has on day-to-day activities, and only 32% to 34% responded positively, with 18% to 22% responding strongly. In contrast, 60% of the interviewees described having pain, and among these interviewees, 55% and 85% reporting a high or some/high impact on QOL, respectively. A similar trend existed for sadness/ depression, particularly with the PROMIS items.
For other concepts, including fatigue (on FACT and PROMIS), family impact, economic impact, and nausea (on FACT), the prevalence and impact based on interview statements correlated well with the scores for corresponding survey items.
DISCUSSION
Our cross-sectional study elicited both positive and negative concepts for inclusion in the AML-QOL and provided guidance for avoiding confusion or ambiguity in the drafting of the instrument. Some of our results are similar to those reported in previous studies of newly Original Article diagnosed and recently relapsed patients with acute (mostly myeloid) leukemia that used the Memorial Symptom Assessment Scale to describe symptom burden. 15, 16 Although those investigators noted more prevalent side effects of chemotherapy (because >90% of the members of each cohort were receiving chemotherapy), their reported prevalence for emotional concepts such as fear/ anxiety was much lower than ours, and this possibly reflects differences in study techniques with questionnaire-elicited symptoms versus interview-elicited symptoms. Several chemotherapy-related side effects, including decreased appetite (23%), taste changes (22%), and fevers (21%), had a low prevalence in our study, likely because 29 of the 44 patients receiving chemotherapy (66%) were within 5 days of starting or had already recovered their counts and were less likely to be experiencing some of these toxicities.
Results from our study allowed us to draft a preliminary version of the AML-QOL, which includes 40 questions covering 5 positive concepts and 21 negative concepts. Concepts with higher prevalence-impact scores are represented with more questions to include more wording choices for particularly important concepts. We did not incorporate items from the 29-item PROMIS questionnaire that were identified as sources of ambiguity or confusion in the study population. Item wording is based on speech patterns and themes drawn from patient interviews.
We also took into account the sources of ambiguity and confusion expressed by patients about established instruments. In particular, we were attentive to the distinction between temporary functional restrictions and true functional limitations. For example, a question about leisure activity might read as "I'm not able to do things that I enjoy," but we chose to include "I don't think I'll be able to get back to doing all the things I enjoy." The latter represents a fear or state of permanence, and patients who face temporary restrictions in their functional ability might answer differently than those with perhaps longstanding (and likely more troublesome) limitations.
Although our study comprised a large number of interviews and extended well beyond content saturation, it is limited by having been conducted at a single academic institution. It is possible that patients in other geographic areas or at smaller community hospitals might experience their disease and their health-related QOL differently. Furthermore, of the 51 patients receiving AML-directed therapy at the time of their interview, 45 were receiving intensive cytotoxic chemotherapy; this reflects practice patterns at our center. Although this distribution may be useful in the construction of an instrument intended for use in clinical trials testing intensive regimens, it is a potential limitation for broader applications of the instrument.
Validation of the AML-QOL with patients, caregivers, and medical providers is ongoing to ensure that it is comprehensible and unambiguous and contains appropriate content. The most updated version of the instrument is available upon request. We intend for the AML-QOL to undergo prospective validation at multiple centers and across a variety of treatment types to ensure that our instrument is not specific to patients undergoing intensive therapy at our institution. Our ultimate goal is to create a well-validated and concise instrument that can be used to document and assess the impact of AML and its treatment on patients' QOL.
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